Light Mode
$0.0001 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.0001, and at the day’s high of $0.0001
-0.00 (-75.00%) / 6M
Momentum, market sentiment, and recent alerts
CNBX reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -66.7%.
No alerts for CNBX in the last day.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
CNBX Pharmaceuticals, Inc. is a clinical stage company, which engages in the discovery, development, and commercialization of cannabinoid-based products and technologies for the treatment of cancer. Its products include Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS), and RCC-33, an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC). The company was founded by Eyal Barad on September 15, 2004 and is headquartered in Bethesda, MD.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.